N
Nuria Navarro Coy
Researcher at University of Leeds
Publications - 10
Citations - 804
Nuria Navarro Coy is an academic researcher from University of Leeds. The author has contributed to research in topics: Multiple myeloma & Thalidomide. The author has an hindex of 7, co-authored 10 publications receiving 761 citations. Previous affiliations of Nuria Navarro Coy include Leeds Teaching Hospitals NHS Trust & Chapel Allerton Hospital.
Papers
More filters
Journal ArticleDOI
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Gareth J. Morgan,Walter M Gregory,Faith E. Davies,Sue E. Bell,AJ Szubert,Julia Brown,Nuria Navarro Coy,Gordon Cook,Nigel H. Russell,Claudius Rudin,Huw Roddie,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Graham Jackson,J. Anthony Child +15 more
TL;DR: Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit, and iFISH testing is important in assessing the clinical impact of maintenance therapy.
Journal ArticleDOI
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Nigel H. Russell,Sue E. Bell,AJ Szubert,Nuria Navarro Coy,Gordon Cook,Sylvia Feyler,Jennifer Byrne,Huw Roddie,Claudius Rudin,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Graham Jackson,J. Anthony Child +16 more
TL;DR: In elderly patients with newly diagnosed multiple myeloma (median age, 73 years), CTDa produced higher response rates than MP but was not associated with improved survival outcomes, which highlights the importance of cytogenetic profiling at diagnosis and effective management of adverse events.
Journal ArticleDOI
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Sue E. Bell,AJ Szubert,Nuria Navarro Coy,Gordon Cook,Sylvia Feyler,Peter R. E. Johnson,Claudius Rudin,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Nigel H. Russell,Graham Jackson,J. Anthony Child +15 more
TL;DR: Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
The TRACTISS Protocol:: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome
Sarah Brown,Nuria Navarro Coy,Nuria Navarro Coy,Costantino Pitzalis,Paul Emery,Paul Emery,Sue Pavitt,Janine Gray,Claire Hulme,Frances Hall,Robert Busch,Robert Busch,Peter M. Smith,Luke Dawson,Michele Bombardieri,Ng Wan-fai,Colin T. Pease,Elizabeth Price,Nurhan Sutcliffe,Clodagh Woods,Sharon Ruddock,Colin C Everett,Catherine Reynolds,Emma Skinner,Ana Poveda-Gallego,John Rout,Iain Macleod,Saaeha Rauz,Simon J Bowman +28 more
TL;DR: The TRACTISS trial will provide direct evidence as to whether rituximab in patients with PSS leads to an improvement in patient symptoms and a reduction in disease damage and activity.
Journal ArticleDOI
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Sue E. Bell,Alex J Szubert,Kim Cocks,Nuria Navarro Coy,Mark T. Drayson,Roger G. Owen,Fiona M. Ross,Graham Jackson,J. Anthony Child +11 more
TL;DR: The benefit of the addition of thalidomide to myeloma treatment is shown but also the importance of later analysis of such trials because of the emergence of significant changes at these later time points is highlighted.